CKD-702 Plus Irinotecan in Gastric Cancer

CKD-702 Plus Irinotecan as a ≥3L Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas Overexpressing EGFR or MET

CKD-702 is a tetravalent bispecific IgG1 targeting hepatocyte growth factor receptor (MET) and epidermal growth factor receptor (EGFR). The investigators will test a hypothesis that CKD-702 may augment the efficacy of biweekly irinotecan as a 3L or later therapy for gastric cancer overexpressing either MET or EGFR.

Inclusion Criteria:

• Failed 2 or more lines of chemotherapy
• Tumor overexpressing either MET or EGFR
• Measurable lesion

Exclusion Criteria:

• Prior treatment with anti-MET/EGFR bispecific antibody